Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer
Bibliographic record
Abstract
Plain Language SummaryWhat is this summary about?There are few treatment choices for people with non-small cell lung cancer (NSCLC) when it gets worse after prior treatments. Available treatments lead to poor survival outcomes and severe side effects.This summarizes the results of a study called EVOKE-01. This study compared a newer medicine called sacituzumab govitecan (brand name: TRODELVY®) with a commonly used chemotherapy called docetaxel. People in the study had NSCLC that was advanced or had become metastatic after being treated with other medicines that contain platinum plus an immunotherapy.What were the results?After a median of 13 months of observation in the study, people with advanced or metastatic NSCLC who were treated with sacituzumab govitecan did not live significantly longer than those who were treated with docetaxel. However, similar to docetaxel, many people were helped by sacituzumab govitecan treatment, and patients taking sacituzumab govitecan appeared to live somewhat longer than those who were given docetaxel.People were helped no matter what type of NSCLC they had. The positive effects of sacituzumab govitecan treatment were more obvious in people whose disease did not get better after their last immunotherapy. People given sacituzumab govitecan had fewer severe side effects. Fewer had to stop sacituzumab govitecan treatment, compared with those who were given docetaxel. People who got sacituzumab govitecan in this study had similar side effects as people who took sacituzumab govitecan in other studies. Shortness of breath is a key symptom of NSCLC. People who got sacituzumab govitecan took longer to have shortness of breath compared with people who got docetaxel. This suggests that sacituzumab govitecan controlled the disease better than docetaxel.What do the results mean?This study suggested that some people with advanced or metastatic NSCLC might live slightly longer when treated with sacituzumab govitecan than with docetaxel, especially those whose cancer did not respond to earlier treatment with immunotherapy. In this study, about the same number of people who got sacituzumab govitecan or docetaxel had any side effects. Fewer people had severe/life-threatening side effects or had to stop treatment because of side effects with sacituzumab govitecan than docetaxel. These results support future studies of sacituzumab govitecan as a potential treatment for people with previously treated advanced or metastatic NSCLC.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-text
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".